Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18f-alfatide
- Development stage
- Phase 3
- Lead developer
- Jiangsu Shimeikang Pharmaceutical
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
18F-alfatide (also known as 18F-AlF-NOTA-PRGD2 or Alfatide I) is a radiopharmaceutical imaging agent designed for positron emission tomography (PET) imaging of angiogenesis. It consists of a dimeric arginine-glycine-aspartic acid (RGD) peptide (PRGD2) conjugated to a NOTA chelator and radiolabeled with fluorine-18 using an aluminum fluoride ([18F]AlF) complex. The agent specifically targets integrin αvβ3, a cell surface receptor that is significantly overexpressed on angiogenic endothelial cells and various malignant tumor cells. By binding to these receptors, 18F-alfatide allows for the non-invasive visualization and quantification of tumor-induced angiogenesis. It has been investigated in clinical trials for the diagnosis and staging of various cancers, including non-small cell lung cancer (NSCLC), breast cancer, and metastatic lesions in the brain and bone. The compound can be produced using a simple lyophilized kit formulation, allowing for rapid radiofluorination.
- Brand names
- 18F-Alfatide Injection
- Other names
- 18F-Al-NOTA-PRGD218F-RGD PET/CT18F-AlF-NOTA-RGD
02
Targets
αVβ3 (Integrin αVβ3)
Beyond the preview
Go deeper on 18f-alfatide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 18f-alfatide.